<DOC>
	<DOCNO>NCT01756157</DOCNO>
	<brief_summary>The primary objective study evaluate safety , tolerability , efficacy two dos CINRYZE recombinant human hyaluronidase ( rHuPH20 ) administer subcutaneous ( SC ) injection prevent angioedema attack .</brief_summary>
	<brief_title>Subcutaneous CINRYZE With Recombinant Human Hyaluronidase Prevention Angioedema Attacks</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<criteria>Be â‰¥12 year age . Have confirm diagnosis Hereditary Angioedema . Receipt C1 inhibitor ( C1 INH ) therapy blood product treatment prevention angioedema attack within 7 day first dose study drug . Be receive prophylactic intravenous CINRYZE exceeds 1000 unit every 3 4 day ( maximum weekly dose 2000 unit ) . Have receive androgen therapy ( e.g. , danazol , oxandrolone , stanozolol , testosterone ) within 7 day prior first dose study drug . If female , start take change dose hormonal contraceptive regimen hormone replacement therapy ( i.e. , estrogen/progestin contain product ) within 3 month prior first dose study drug . History allergic reaction C1 INH product , include CINRYZE blood product . History abnormal blood clotting . Have know allergy hyaluronidase ingredient study formulation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Crossover</keyword>
	<keyword>Prevention</keyword>
	<keyword>Hereditary Angioedema</keyword>
	<keyword>C1 esterase inhibitor</keyword>
	<keyword>C1 inhibitor</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Recombinant human hyaluronidase</keyword>
</DOC>